Skip to main content
. 2016 Mar 8;7(15):20945–20952. doi: 10.18632/oncotarget.7976

Figure 1. Serum concentration of Tenascin-C in healthy controls and non-small-cell bronchogenic carcinoma (NSCSC) patients.

Figure 1

A. Bars represent the mean of n= 76 healthy controls and n = 116 NSCLC patients as determined by ELISA (p<0.013). B. Receiver operating characteristic (ROC) curves of Tenascin-C for the diagnosis of NSCLC patients versus healthy control samples.